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Introduction: Poor cell survival and limited functional benefits have restricted the efficacy of bone marrow
mesenchymal stem cells (BMSCs) in the treatment of myocardial infarction. We showed recently that hypoxia
preconditioning of BMSCs and neural progenitor cells before transplantation can enhance the survival and
therapeutic properties of these cells in the ischemic brain and heart. The present investigation explores a novel
strategy of preconditioning BMSCs using the Hypoxia-inducible factor 1α (HIF-α) prolyl hydroxylase inhibitor
dimethyloxalylglycine (DMOG) to enhance their survival and therapeutic efficacy after transplantation into infarcted
myocardium.
Methods: BMSCs from green fluorescent protein transgenic rats were cultured with or without 1 mM DMOG for
24 hours in complete culture medium before transplantation. Survival and angiogenic factors were evaluated
in vitro by trypan blue staining, Western blotting, and tube formation test. In an ischemic heart model of rats,
BMSCs with and without DMOG preconditioning were intramyocardially transplanted into the peri-infarct region
30 minutes after permanent myocardial ischemia. Cell death was measured 24 hours after engraftment. Heart
function, angiogenesis and infarct size were measured 4 weeks later.
Results: In DMOG preconditioned BMSCs (DMOG-BMSCs), the expression of survival and angiogenic factors
including HIF-1α, vascular endothelial growth factor, glucose transporter 1 and phospho-Akt were significantly
increased. In comparison with control cells, DMOG-BMSCs showed higher viability and enhanced angiogenesis in
both in vitro and in vivo assays. Transplantation of DMOG-BMSCs reduced heart infarct size and promoted functional
benefits of the cell therapy.
Conclusions: We suggest that DMOG preconditioning enhances the survival capability of BMSCs and paracrine
effects with increased differentiation potential. Prolyl hydroxylase inhibition is an effective and feasible strategy to
enhance therapeutic efficacy and efficiency of BMSC transplantation therapy after heart ischemia.* Correspondence: lwei7@emory.edu
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Myocardial infarction (MI) is a leading cause of congest-
ive heart failure that results from irreversible loss of car-
diomyocytes, scar formation and ventricular remodeling
[1]. A large amount of animal and clinical research has
demonstrated that bone marrow mesenchymal stem cells
(BMSCs) are capable of improving the post-MI recovery
due to continued self-renewal, transdifferentiation and
paracrine effects [2]. However, the morphological and
functional benefits of BMSC therapy are limited primar-
ily due to the low survival rate of transplanted cells in
the ischemic host environment [3]. Strategies to improve
BMSC tolerance to hypoxic/ischemic conditions as well
as their functional benefits are therefore critically needed
for clinical translation of the cell therapy.
Earlier work demonstrated that pretreatment of adult
BMSCs with cardiomyogenic growth factors before trans-
plantation improves the cells’ in vivo cardiac differenti-
ation as well as functional recovery in a dog model of the
chronically infarcted myocardium [4]. In a recent study, a
recombinant cocktail consisting of transforming growth
factor beta-1, bone morphogenetic protein-4, activin A,
retinoic acid, insulin-like growth factor-1, fibroblast
growth factor-2, α-thrombin, and interleukin-6 was
formulated to engage human mesenchymal stem cells into
cardiopoiesis. Compared with unguided counterparts, car-
diopoietic mesenchymal stem cells delivered into infarcted
myocardium achieved superior functional and structural
benefits [5]. In order to enhance cell survival and repair
potential, some studies have overexpressed anti-apoptotic
and trophic/growth factors in stem cells or progenitor
cells [6-9]. This molecular biological approach can effect-
ively reduce cell death; however, it causes a practical con-
cern for increased risk of tumor growth due to lasting and
high expression of anti-apoptotic factors. Alternatively, we
recently explored a new approach of hypoxic precondi-
tioning by exposing stem cells and progenitor cells to sub-
lethal hypoxia before transplantation [10]. This hypoxic
preconditioning increased the expression of prosurvival
and proangiogenic factors including hypoxia-inducible
factor (HIF)-1α, angiopoietin-1, vascular endothelial growth
factor (VEGF) and its receptor Flk-1, erythropoietin (EPO),
Bcl-2, and Bcl-xL. Cell death and caspase-3 activation
in these cells was significantly lower compared with that
in normoxic cells both in vitro and after transplantation.
Transplantation of hypoxic preconditioned BMSCs,
neural progenitors or cardiac progenitors, resulted in
greater cell survival, angiogenesis, better tissue repair
and enhanced functional recovery after myocardial and
cerebral ischemia [7,10-18].
It is suggested that a preconditioning procedure sets
cells into a primed state before they encounter the harsh
microenvironment of hypoxia/ischemia and elevated levels
of injurious factors [19,20]. At present, the preconditioningstrategy has been increasingly accepted and applied in
cell-based transplantation therapy and shows multiple
therapeutic benefits after ischemic disorders in the cen-
tral nervous system and peripheral organs [21-23]. Be-
sides hypoxic preconditioning, we and others have
shown that stem cells/neural progenitors can be precon-
ditioned by some endogenous factors and neural pep-
tides such as growth factors, interleukin-6, apelin and
EPO [4,17,18,24-26]. Similarly, pharmacological precon-
ditioning has emerged as a means of priming trans-
planted cells. For example, pretreatment of skeletal
myoblasts and mesenchymal stem cells with diazoxide
achieved protective and functional benefits in the treatment
of cardiomyocyte ischemia [27,28]. Diazoxide pretreatment
also protects neurons from glutamate toxicity [29].
Prolyl hydroxylases are members of an iron-dependent
and 2-oxoglutamate-dependent dioxygenase enzyme fam-
ily. The HIF prolyl hydroxylase enzymes, termed the pro-
lyl hydroxylase domain, play an important role in oxygen
regulation in different tissues and organs [30]. Cells
recognize and respond to hypoxia by accumulating the
transcription factor HIF-1, composed of oxygen-sensitive
inducible HIF-1α and constitutive HIF-1β subunits. Prolyl
hydroxylase domain enzymes are involved in the degrad-
ation of the HIF-1α subunit. Under hypoxic conditions,
the lack of oxygen leads to stabilization of HIF-1α to form
a HIF heterodimer that is subsequently translocated to
the nucleus, triggering the transactivation of target
genes. The nature of the target gene and type of expressed
proteins may vary depending upon the type of tissues and
disease conditions [31]. Similar effects can be obtained
using the prolyl hydroxylase inhibitor, dimethyloxalylgly-
cine (DMOG). HIF-1α in turns activates the transcription
of a number of angiogenic and survival genes such as
VEGF, glucose transporter 1 (Glut-1), and EPO [32-36].
Our previous study showed that DMOG enhanced cell
survival against the apoptotic insult of serum deprivation
in a dose-dependent manner in BMSC cultures, mediated
by the mechanisms of HIF-1α stabilization, regulation of
the mitochondrial pathway and phosphatidylinositol-4,
5-bisphosphate 3-kinase (PI3K)/Akt activation [37]. DMOG
treatment reduced mitochondrial cytochrome c release,
prevented nuclear translocation of apoptosis inducing fac-
tor, and promoted Akt phosphorylation [37]. In a subse-
quent investigation, we demonstrated in neuronal cultures
that DMOG (100 μM) reduced cell death induced by oxy-
gen glucose deprivation [34]. In a cerebral ischemic stroke
model, DMOG treatment (50 mg/kg, intraperitoneally)
enhanced HIF-1α activation and transcription of its down-
stream genes VEGF, EPO, endothelial nitric oxide synthe-
sis, and pyruvate dehydrogenase kinase-1. The DMOG
treatment reduced caspase-3 activation and infarct forma-
tion and improved functional recovery after stroke [34].
These data suggest that the oxygen-sensing pathway is a
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explores the hypothesis that DMOG, as an inhibitor of the
oxygen-regulated enzyme prolyl hydroxylase, can mimic
the hypoxic environment to prime BMSCs for an effective
transplantation therapy after heart ischemia.
Methods and materials
Bone marrow mesenchymal stem cell cultures
BMSCs from green fluorescent protein transgenic rats
were isolated and harvested as described previously [38].
In brief, bone marrow tissues were acquired by flushing
the cavities of femurs and tibias with basal Dulbecco’s
modified Eagle’s medium. Collected bone marrow cells
were seeded into flasks with Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal bovine serum.
Cells were cultured at 37°C in a humidified environment
with 5% carbon dioxide. Nonadherent cells were removed
24 hours later, and adherent cell colonies were washed
three times with phosphate-buffered saline solution (PBS).
Fresh complete medium was added and changed every 3
to 4 days. Cells were subcultured 1:2 or 1:3 when they
reached 80% confluence. BMSCs of four to six passages
were used in this study.
For identification of BMSCs, cell surface markers CD90,
CD34 and CD45 were detected by fluorescence-activated
cell sorting. The detailed characterization of our isolated
bone marrow cells and multipotency of identified BMSCs
were confirmed in our previous investigations [39]. In the
present investigation, CD90+/CD34–/CD45– cells were se-
lected and tested.
Dimethyloxalylglycine preconditioning of BMSCs
Cells were subcultured at 1:2/1:3 and cultured for 2 to
3 days until they reached 70 to 80% confluence. Cells
were then exposed to fresh complete medium supple-
mented with 1 mM DMOG for 24 hours. The DMOG
concentration was selected based on our previous inves-
tigations [37]. For the nonpreconditioned control, cul-
ture medium was changed to fresh complete medium at
the same time as DMOG treatment. Before transplant-
ation, cells were labeled with Hoechst 33342 by adding a
final concentration of 10 μM/ml in the culture medium
and were incubated for 2 hours to trace BMSCs after
transplantation. BMSCs were then washed six times with
PBS to remove unbound Hoechst dye, and digested with
0.25% (w/v) trypsin ethylenediamine tetraacetic acid,
followed by suspension in complete medium. After several
centrifugations and PBS washes, cells were suspended in a
serum-free medium at 1 × 106 cells per 150 μl. This solu-
tion was injected into five sites (30 μl each) in peri-infarct
myocardium 30 minutes after the ligation of the left anter-
ior descending coronary artery as described previously
[40]. For control, MI rats received the same volume of
serum-free/cell-free medium. Four groups of 10 rats eachwere randomly divided as follows: sham-operated control
group; MI with injection of medium as MI-medium
control; MI with transplantation of nonpreconditioned
BMSCs as N-BMSC control; and MI with transplant-
ation of DMOG-pretreated BMSCs as DMOG-BMSC
control.Myocardial infarction model of rats
All animal experiments and surgical procedures were
approved by the University Animal Research and Use
Committee (IACUC, Emory University; No. 2001421)
and met National Institutes of Health standards. Wis-
tar rats were subjected to general anesthesia with 4%
chloral hydrate (4 mg/kg intraperitoneally) and ventilated
with room air using a small animal ventilator (Vetronics,
Lafayette, IN, USA). MI was induced by ligation of the left
anterior descending coronary artery with a 6–0 silk suture
[10,40]. Successful performance of coronary artery occlu-
sion was verified by the blanching of the myocardium dis-
tal to the coronary ligation.Cell death assessments of Trypan Blue staining in vitro
To evaluate the protective effect of the DMOG precondi-
tioning in vitro, cell death induced by hydrogen peroxide
(100 μM) in a serum-free medium (90 minutes) was tested.
This combination insult was intended to mimic the micro-
environment of a myocardial ischemic attack [41]. Trypan
Blue staining was applied to assess cell death. Serum-free
medium containing 0.05% Trypan Blue was added for
10 minutes and phase contrast images were taken in five
randomly chosen fields per well. The cell death percentage
was determined by the ratio of Trypan Blue-positive cells
to the total number of cells.Terminal deoxynucleotidyl transferase biotin-dUPT nick
end labeling in heart sections
The terminal deoxynucleotidyl transferase biotin-dUPT
nick end labeling (TUNEL) staining kit (DeadEnd™ Fluoro-
metric TUNEL system; Promega, Madison, WI, USA) was
used for detecting cell death in heart sections. After fixing
with 10% buffered formalin phosphate (Fisher Scientific,
Pittsburgh, PA, USA) for 10 minutes, heart sections were
pretreated with −20°C ethanol:acetic acid (2:1) and 0.2%
Triton X-100. The slices were then incubated with an
equilibration buffer as specified by the TUNEL kit. Se-
quentially, the TdT enzyme and nucleotide mix were
added at proportions instructed by the kit for 75 minutes
in a humidified chamber at room temperature. The
slices were then washed with 2× SSC washing buffer for
15 minutes, and finally washed three times with PBS. In
the end, the sections were slip covered and examined
under a florescent microscope.
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Cells were harvested and lysed with modified RIPA buffer
(50 mM HEPES, pH 7.3, 1% sodium deoxycholate, 1% Tri-
ton X-100, 0.1% SDS, 150 mM NaCl, 1 mM ethylenedi-
amine tetraacetic acid, 1 mM Na3VO4, 1 mM NaF, and
protease inhibitor cocktail (Roche, Nutley, NJ, USA)).
Cells were vortexed repeatedly until completely lysed,
followed by centrifugation at 14,000 × g for 20 minutes.
The concentration of proteins from different groups was
determined using the Bicinchoninic Acid Assay (Sigma, St
Louis, MO, USA). All of the above steps were performed
at 4°C.
Proteins (30 to 50 μg) per sample were electrophoresed
on a 6 to 18% gradient gel by SDS-PAGE in a Hoefer
Mini-Gel system (Amersham Biosciences, Piscataway,
NJ, USA) and transferred in a Hoefer Transfer Tank
(Amersham Biosciences) to a PVDF membrane (BioRad,
Hercules, CA, USA). After blockage by 5% milk in Tris-
buffered saline with 0.1% Tween at room temperature
for 2 hours, membranes were incubated with specific
primary antibodies overnight at 4°C. Alkaline phosphatase/
horseradish peroxidase-marked secondary antibodies were
then conjugated at room temperature for 2 hours. Finally,
the expression signals were detected with BCIP/NBT solu-
tion (Sigma) and analyzed by Image-Pro Plus software
(NIH, Bethesda, MD, USA).
Tube formation test
The tube formation test is a well-established assay used
to detect the formation of three-dimensional vessels and
used widely to assess angiogenesis in vitro. Matrigel (Sigma)
was prepared in 24-well plate according to the manufactur-
er's instructions. DMOG-preconditioned (DMOG-BMSCs)
or nonpreconditioned BMSCs were seeded into the coated
wells at a density of 50,000 cells, and were incubated for
6 hours at 37°C for full development of vessel-like tube
structures. Tube formation was quantified by the cumula-
tive tube length. In the case where several tube-like struc-
tures merged together or branched, the total length of
tubes was calculated as the sum of the length of the indi-
vidual branches.
Immunofluorescence staining
For immunofluorescence staining, heart slices were fixed with
10% formalin for 10 minutes, followed by permeabilization
with 0.2% Triton X-100 for 5 minutes and blocked with
1% fish gelatin (Sigma) for 1 hour at room temperature.
Specific primary antibodies were incubated overnight at
4°C in a humidified environment, and washed three
times with PBS. Specimens were then incubated with
Cy3-conjugated Donkey anti-rabbit IgG (1:500; Jackson
ImmunoResearsh, West Grove, PA, USA) or Alexa Fluor
488 anti-goat IgG (1:200; Molecular Probes, Carlsbad, CA,
USA) for 1 hour at room temperature. Nuclear stainingwas performed by treatment with Hoechst 33342 (1:20,000;
Molecular Probes, Carlsbad, CA, USA) for 5 minutes.
Slices were then mounted and observed under a florescent
microscope (BX51: Olympus, Center Valley, PA, USA).
Evaluation of cardiac function
Transthoracic echocardiography and hemodynamic meas-
urement were performed for the analysis of cardiac
function 4 weeks after myocardial ischemia. Rats were
anesthetized with 4% chloral hydrate by intraperitoneal
injection. Echocardiography was performed using a
VisualSonics Vevo 2100 system (VisualSonics, Inc.,
Toronto, ON, Canada) with a 12.0 MHz transducer. The
left ventricular end-diastolic diameters and left ventricular
end-systolic diameters were measured by two-dimensional
targeted M-mode, and the left ventricular ejection fraction
(LVEF) was calculated:
LVEF %ð Þ ¼ ððleft ventricular end‐diastolic volume
‐ left ventricular end‐systolic volumeÞ
=left ventricular end‐diastolic volumeÞ  100
Using echocardiographic evaluation, hemodynamic
measurement was performed. After right carotid artery
exposure, a microtip catheter was cannulated into the
left ventricle and was connected with a MLT0699 dis-
posable pressure transducer (AD Instrument, Colorado
Springs, CO, USA). The left ventricular systolic pressure
(LVSP), left ventricular end-diastolic pressure (LVEDP),
maximum change rate of left ventricular pressure rise and
fall (±dp/dt), time constant of the isovolumic pressure
decline (Tau) and heart rate were monitored and re-
corded using the Powerlab/800 data acquisition system
(AD Instrument).
Measurement of infarct size
Rats were sacrificed after measuring hemodynamics by
an overdose of anesthetic. Hearts were harvested quickly
and split into transverse sections: apex, mid left ventricle,
and base. The tree sections of the hearts were embedded
in optimal cutting temperature compound (Sakura Finetek
USA Inc., Torrance, CA, USA). Samples cut at 10 μm
thickness were stained with Masson’s trichrome and im-
ages of each slide were digitized through the NIH image
analysis system. The percentage of infarct size/fibrotic
area was calculated by dividing the sum of epicardial and
endocardial circumference of the infarcted area by the
sum of the total endocardial and epicardial circumference
of the left ventricle [42].
Statistical analysis
Data were analyzed with SPSS 13.0 (IBM Corp.
Armonk, NY, USA) and expressed as mean ± standard
error of mean. Student’s two-tailed t test was applied for
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one-way analysis of variance followed by the Tukey post
hoc test for multiple comparisons. Statistical significance
was defined as P <0.05.
Results
Upregulation of survival and angiogenic factors in
DMOG-preconditioned BMSCs
To evaluate the effect of DMOG preconditioning on
BMSCs, we first analyzed the expression of survival and
angiogenic proteins in control BMSCs (C-BMSCs) and
DMOG-treated BMSCs (DMOG-BMSCs) using western
blot analysis. HIF-1α, VEGF, Glut-1 and phospho-Akt
were detected in both groups of BMSCs. However, sig-
nificantly higher expressions of HIF-1α and the down-
stream factors Glut-1 and VEGF were seen in DMOG-
BMSCs compared with C-BMSCs. Akt activation was
markedly increased by DMOG preconditioning so that
the ratio of phospho-Akt/Akt increased approximately
10-fold compared with C-BMSCs (Figure 1).
Dimethyloxalylglycine preconditioning reduced BMSC cell
death in vitro and after transplantation
To examine whether DMOG-induced preconditioning
could increase the tolerance of BMSCs, cell death was firstFigure 1 Effect of dedimethyloxalylglycine preconditioning on the ex
marrow mesenchymal stem cells (BMSCs) were cultured with or without de
factor (HIF)-1ɑ, glucose transporter 1 (Glut-1), vascular endothelial growth f
Beta-actin was used as the loading control. (B) Densitometric analysis was
proteins in DMOG-BMSCs with respect to vehicle control BMSCs (C-BMSCs)
compared with C-BMSC group. (C) Ratio of phospho-Akt against total Akt e
10-fold Akt phosphorylation was seen in DMOG-BMSCs compared with conexamined in BMSC cultures, which helped to determine
the protective effect of different durations of DMOG
pretreatment. In the Trypan Blue assay, hydrogen per-
oxide (6 to 24 hours) caused significantly more than
50% cell death in C-BMSC cultures, while DMOG pre-
treatment of 6, 12 and 24 hours showed time-dependent
protective effects. Trypan Blue-positive cells were signifi-
cantly reduced in DMOG-treated cells, with the strongest
protection induced by 24-hour DMGO pretreatment
(Figure 2). The cell death rate in this group decreased
from 52.4 ± 4.8% to 18.1 ± 0.4% (n =4, P <0.05). Based
on this observation, we selected the 24-hour DMOG ex-
posure in our preconditioning procedure in the follow-
ing experiments.
To evaluate whether DMOG-BMSCs could show en-
hanced survival in vivo, C-BMSCs and DMOG-BMSCs
were implanted into the peri-infarct region 30 minutes
after the left anterior descending ligation in rats. Ani-
mals were sacrificed 24 hours later to identify the fate of
transplanted BMSCs. This time point was selected be-
cause the majority of cell death after transplantation oc-
curred within 24 hours [3]. Cell death was identified by
the ratio of TUNEL/Hoechst/green fluorescent protein
co-labeled cells versus total Hoechst/green fluorescent
protein-positive cells (Figure 2B,C,D,E,F,G). In thepression of prosurvival and angiogenic factors. (A) Rat bone
dimethyloxalylglycine (DMOG, 1 mM) for 24 hours. Hypoxia-inducible
actor (VEGF) and phospho-Akt were then detected by western blotting.
applied for comparison of the relative expression levels of different
that is arbitrarily presented as 1. n =3 independent assays. *P <0.05
xpression, quantified from the western blot gels. A large increase of
trol BMSCs. n =3 independent assays. *P <0.05 vs. control cells.
Figure 2 Effect of dedimethyloxalylglycine preconditioning on cell death in vitro and after transplantation. (A) Hydrogen peroxide
(H2O2)-induced cell death was measured in bone marrow mesenchymal stem cell (BMSC) cultures with and without dedimethyloxalylglycine
(DMOG) preconditioning. After different durations of DMOG (1 mM) treatment, cell death was induced by H2O2 (100 μM) in a serum-free medium
for 90 minutes. The membrane-permeable dye Trypan Blue was added 5 to 10 minutes before cell death measurement. Damaged BMSCs were
identified as cells unable to exclude the blue color dye from the cytosol. n =3 independent tests in each time group. *P <0.05 compared with
C-BMSC group. #P <0.05 compared with basal control group. (B) to (E) Green fluorescent protein (GFP)-positive BMSCs (green) were labeled with
Hoechst 33342 (blue) before transplantation to further facilitate tracking transplanted cells. Cell death was evaluated 24 hours after transplantation
using terminal deoxynucleotidyl transferase biotin-dUPT nick end labeling (TUNEL) staining (red) in heart sections. Co-labeling of GFP/Hoechst/
TUNEL fluorescence was designated as transplanted dead BMSCs. (F) Summarized cell count data of GFP/Hoechst/TUNEL-positive cells against
total exogenous (GFP/Hoechst-positive) cells. n =4 independent experiments in each group. *P <0.05 compared with C-BMSC group.
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TUNEL-positive. While transplanted DMOG-BMSCs
showed significantly less death, there were 62.8 ± 3.1%
TUNEL-positive cells among the total transplanted cells
(Figure 2F).
Dimethyloxalylglycine preconditioning enhanced angiogenic
activities of BMSCs in vitro and after transplantation
The effect of DMOG preconditioning on BMSC-induced
angiogenesis was examined in vitro and in vivo. For in vitrostudies, tube formation stimulated by Matrigel was tested.
Although C-BMSCs were able to form vessel tubes in re-
sponse to Matrigel, DMOG-BMSCs formed more tubes
and the total tube length was significantly longer (1.9-fold)
than that formed by C-BMSC (Figure 3A,B,I). To assess
angiogenic activity after transplantation, we stained the
endothelial marker von Willebrand factor in heart sec-
tions. Both BMSC transplantation groups presented in-
creased vessel density/area compared with the MI control
group. Transplantation of DMOG-BMSCs showed even
Figure 3 Effect of dedimethyloxalylglycine preconditioning on angiogenesis in vitro and after transplantation. (A), (B) Tube formation
test stimulated by Matrigel was performed to identify the angiogenic activity of control bone marrow mesenchymal stem cells (C-BMSCs) and
dedimethyloxalylglycine-preconditioned BMSCs (DMOG-BMSCs) in vitro. (C) to (H) Angiogenesis was inspected using von Willebrand factor
staining (red) in heart sections from the myocardial infarction (MI), C-BMSC and DMOG-BMSC groups 4 weeks after MI. Hoechst staining (blue)
shows the total cells. (I) Summary of total tube length measured in (A) and (B). The total tube length in the C-BMSC group was arbitrarily presented
as 1. n =3 independent measurements. (J) Summary of total vessel density in different groups of in vivo experiments. n =8 animals in each
group. *P <0.05 compared with C-BMSC group; #P <0.05 compared with MI control group.
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were observed in the DMOG-BMSC group compared
with the C-BMSC group (Figure 3C,D,E,F,G,H,J).
Reduced infarct size after transplantation of BMSCs
Masson’s trichrome staining was used to assess fibrosis
and scar formation 4 weeks after myocardial infarctionand BMSC transplantation. Obvious infarct and scar for-
mation was observed in the ischemic hearts that received
cell-free medium injection. In comparison, the infarct size
in both C-BMSC and DMOG-BMSC implantation groups
was significantly smaller. Transplantation of DMOG-
BMSCs resulted in the smallest infarct size in the is-
chemic heart (Figure 4).
Figure 4 Effect of bone marrow mesenchymal stem cell transplantation on ischemia-induced infarct formation. Heart infarct area and
scar formation were determined using Masson’s Trichrome staining 4 weeks after myocardial infarction (MI). (A) to (C) Images of representative
infarcted hearts from a MI control rat, a MI rat receiving control bone marrow mesenchymal stem cells (C-BMSCs), and a MI rat receiving
dedimethyloxalylglycine-preconditioned BMSCs (DMOG-BMSCs). (D) Transplantation of BMSCs reduced heart infarction formation; the protective
effects were significantly greater with transplantation of DMOG-BMSCs. n =5 rats in each group. *P <0.05 compared with MI group; #P <0.05
compared with C-BMSC group.
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The ischemic heart functional recovery after BMSC trans-
plantation was measured by the changes in LVSP, LVEDP,
+dp/dt, −dp/dt, Tau and LVEF 4 weeks after ischemia and
treatments. Compared with the MI control group, trans-
plantation of both C-BMSCs and DMOG-BMSCs facili-
tated better cardiac recovery, shown as increased LVSP
and absolute values of ± dp/dt, and decreased Tau and
promotion of LVEF (Figure 5). However, C-BMSC trans-
plantation had no effect on the value of LVEDP, while
DMOG-BMSC transplantation significantly reduced the
LVEDP value to a near-normal level. Furthermore, even
better recovery shown as significantly higher LVSP, en-
hanced ± dp/dt, lower LVEDP and TAU, and ameliorated
LVEF was seen in MI rats receiving DMOG-BMSCs
(Figure 5).
Discussion
The present investigation demonstrates for the first time
that the prolyl hydroxylase inhibitor DMOG can be used
to prime BMSCs in cell-based transplantation therapy
after heart ischemia. We show that DMOG-pretreated
BMSCs are more resistant to death both in vitro and
after transplantation into the ischemic heart. DMOG-
BMSCs show enhanced angiogenic activities. Survivaland angiogenic factors such as HIF-1α, VEGF, Glut-1 and
phospho-Akt increased after DMOG preconditioning, a
typical gene regulation usually seen with hypoxic precon-
ditioning. Transplantation of DMOG-BMSCs also leads to
better recovery of the heart function in the rat’s MI model.
It is thus likely that, as a regulator of the oxygen sensing
system, DMOG can be used as an alternative way of pre-
conditioning stem cells/progenitors. Like hypoxic precon-
ditioning, DMOG preconditioning can optimize BMSC
viability and regenerative capability for better engraftment
and/or functional benefit in the harsh environment of
myocardial infarction.
We and others have shown that the prolyl hydroxylase
inhibitor DMOG prevents acute damage in the ischemic
heart and brain as well as ameliorating BMSC cell death
under pathological conditions [34,37,43]. However, DMOG
has not been tested as a preconditioning reagent for stem
cell therapy. So far, there has been only one related report
showing that intraperitoneal injection of DMOG 48 hours
before a skin ischemic insult could improve skin flap
survival [44]. Fewer apoptotic cells were present in the
ischemic flaps of DMOG-treated mice. Marked in-
creases in circulating endothelial progenitor cells and
bone marrow proliferative progenitor cells were observed
after DMOG treatment [44]. We can now consistently
Figure 5 Effect of bone marrow mesenchymal stem cell transplantation on functional recovery after heart ischemia. Heart function was
measured 4 weeks after myocardial infarction (MI) and cell transplantation treatment. MI rats showed functional deficits in all measurements of
(A) left ventricular systolic pressure (LVSP), (B) left ventricular end-diastolic pressure (LVEDP), (C) maximum change rate of left ventricular pressure
rise and fall (±dp/dt), (D) minimum change rate of left ventricular pressure rise and fall (–dp/dt), (E) time constant of the isovolumic pressure
decline (Tau) and (F) left ventricular ejection fraction (LVEF). BMSC transplantation improved functional parameters of MI rats. Rats received
dedimethyloxalylglycine-preconditioned BMSCs (DMOG-BMSCs) showed the enhanced functional recovery in all four functional parameters.
n =8 rats in each group. *P <0.05 compared with MI-only group. #P <0.05 compared with the control BMSC (C-BMSC) group.
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new method of triggering endogenous beneficial mech-
anisms without applying hypoxic treatments.
Current strategies of BMSC transplantation achieve
only modest recovery of cardiac deficits largely because
of acute-phase cell death after implantation into the in-
farcted myocardium [3]. One limitation is that, as multi-
potent cells, the transdifferentiation efficiency of BMSCs
into cardiac lineage cells is low and their engraftment in
the ischemic heart is not clear [45]. The present investi-
gation focuses on the survival and increased paracrine
factors in preconditioned cells. Whether transplanted
BMSCs became cardiomyocytes or vascular endothelial
cells and whether DMOG preconditioning enhances
the transdifferentiation in vivo remain to be examined.
In cell transplantation therapy, besides selections of
ideal timing and the route of cell transplantation, it has
also become important to test gene modification and cell
preconditioning for increased cell survival [2,7,25,46,47].
A concern with regards to gene modification is whether
or not permanent gene modification would increase the
risk of tumorigenesis. Permanent or long-term gene modi-
fication in cell-based therapy may therefore be of limited
use in clinical applications [48]. Since preconditioning
strategies usually modify related genes in a relatively short
period (days to weeks), this approach may be more feasible
for clinical applications. To this end, hypoxic precondition-
ing has been shown highly effective in transplantation ther-
apy using several stem cells and neural progenitor cells
after ischemic stroke and other disorders [21,39]. For ex-
ample, our group was among the first to report that hyp-
oxic preconditioning could be applied to stem cell therapy
for enhanced cell survival and optimized regenerative cap-
abilities including enhanced angiogenesis, neurogenesis,
suppressing inflammatory response, improved directed
cell migration, homing to the ischemic region, and finally
better functional recovery after heart and brain ischemia
[7,15-17]. Since then a number of preconditioning media-
tors and pharmacological reagents have been tested for
the preconditioning of different cells [18,19].
Our previous findings showed that both the HIF-1α
pathway and the PI3K/Akt signaling were involved in
the DMOG protective mechanisms [37]. In accordance
with this, we found HIF-1α and Akt pathways were both
activated in DMOG-BMSCs. HIF-1α plays an important
role in vascular development and embryonic lethality. In
HIF-1α−/− mice, defects in angiogenesis have been ob-
served in both the yolk sac and the developing embry-
onic tissues [49]. HIF-1α stabilization and enhanced
VEGF expression followed by prolyl hydroxylase inhib-
ition increased lung angiogenesis in the primate model
of bronchopulmonary dysplasia, a chronic form of lung
disease [50]. HIF-1α stabilization is a major stimulus for
increased VEGF production that plays a pivotal role inangiogenesis. Activation of the PI3K/Akt pathway can
also increase VEGF secretion both by HIF-1-dependent
and HIF-1-independent mechanisms [51]. These observa-
tions are consistent with our observation that HIF-1α and
the PI3K/Akt pathway, as well as some downstream mole-
cules such as VEGF, contribute to the protective and regen-
erative benefits with DMOG preconditioning of BMSCs.
Conclusion
We conclude that targeting an oxygen sensing system
such as prolyl hydroxylase provides a new promising
pharmacological approach for enhanced survival of BMSCs,
increased paracrine signaling, augmented regenerative ac-
tivities and improved functional recovery in cell trans-
plantation therapy for the ischemic heart. The present
data and previous evidence support a possible precondi-
tioning benefit of increased transdifferentiation of BMSCs
into cardiac lineage cells.
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